Dra. Kreina Sharela Vega Cano

CURRENT POSITION
Gastrointestinal Cancer Unit, Vall d’Hebron University Hospital & VHIO – Barcelona, Spain
May 2024 – Present
● Attending physician focused on management of GI malignancies, multidisciplinary team care, and molecular-driven therapeutic decision-making.

EDUCATION & CERTIFICATIONS
● Master in Medical Oncology – SEOM (Spanish Society of Medical Oncology), 2023–2024
● Master in Molecular Oncology – Universidad Rey Juan Carlos / CNIO, 2022–2023
ESMO Certification – Passed European Society for Medical Oncology Board Exam, 2023
● Medical Oncology Residency – Vall d’Hebron University Hospital, 2019–2024
● Medical Degree (MD) – Universidad Mayor de San Simón, Bolivia, 2011–2016

AFFILIATIONS
● European Society for Medical Oncology (ESMO)
● Spanish Society of Medical Oncology (SEOM)
● Catalan-Balearic Society of Medical Oncology
● Spanish Digestive Tumor Treatment Group

PUBLICATIONS
● Álvarez-Gallego, Rafael; Macarulla T; Laquente B; Peinado P; Castet F, Muñoz C,; Fabregat-Franco C; Vega-Cano, Kreina Sharela; et al. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX. American Journal of Clinical Oncology. 48 - 9, pp. 470 - 476. Wolters Kluwer Health,Inc., 10/09/2025. ISSN 0277-3732. DOI: 10.1097/COC.0000000000001253
● Vega Cano KS, Florian Castet, Virginia Genovesi, Eduardo Teran, Teresa Macarulla. Lenvatinib en el carcinoma hepatocelular avanzado: posicionamiento actual y perspectivas futuras. Revisiones en Cáncer. Accepted, in press (2025).
● Muñoz-Martín AJ, Castet F, Soto J, Vega Cano KS, et al. MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry. ESMO Gastrointest Oncol. 2025;8(C):100187. doi:10.1016/j.esmogo.2025.100187
● Cruellas M, Papakonstantinou A, López-Fernández A, Vega KS, et al. Identifying germline pathogenic variants in breast cancer using tumor sequencing. The Breast. 2025;81:102511. doi:10.1016/j.breast.2024.102511.
● Vega Cano KS, Marmolejo Castañeda DH, Escrivá-de-Romaní S, Saura C. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. Cancers (Basel). 2023;15(1):51. doi:10.3390/cancers15010051
● Mirallas Viñas O, Martin Cullell B, Navarro V, Alonso M, Vega Cano KS, et al. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool). Lancet Reg Health Eur. 2024;46:101063. doi:10.1016/j.lanepe.2024.101063
● Galip Can Uyar, Mirallas O, Baskurt K, Martin-Cullell B, Yesilbas E, Recuero-Borau J, Kaya S, Navarro-Garcé V, Eryildiz Yucel S, Vega Cano KS, et al. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. The Lancet Regional Health – Europe. 2025;54. doi:10.1016/j.lanepe.2025.101317
● Vega-Cano KS, Cordero-Vázquez E, Mestre-Torres J. Hypoglycemia as a form of presentation of pituitary infiltration by lymphoma. Med Clin (Barc). 2021;156(7):362–363. doi:10.1016/j.medcli.2020.01.040
● Saoudi González N, Salvà F, Ros J, Baraibar I, Rodríguez-Castells M, Vega-Cano KS, et al. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications. Cancers (Basel). 2023;15(16):4020. doi:10.3390/cancers15164020


CONGRESS COMMUNICATIONS (First Author)
ESMO Congress 2025, Berlin, Germany. Abstract FPN: 2253P. Clinical and molecular predictors of response to Chemotherapy (CT) in advanced Pancreatic Cancer (PC).
SEOM 2025, Madrid, Spain. Clinical and molecular characteristics in patients with advanced pancreatic cancer: retrospective analysis at a tertiary care center.
EASL Congress 2025. Liver injury induced by CDK4/6 inhibitors for metastatic breast cancer: characterization and management. Data from a multicenter study. Amsterdam, Netherlands. May 7–10, 2025.
EASL Congress 2024. Combination of liver steatosis and premenopausal status is a risk factor for DILI due to CDK4/6 inhibitors as first-line treatment for metastatic breast cancer. Milan, Italy. June 5–8, 2024. Journal of Hepatology. 80, p. 702. DOI: 10.1016/S0168-8278(24)01994-9
ESMO Congress 2024. The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials. Barcelona, Spain. September 13–17, 2024. Annals of Oncology. DOI: 10.1016/j.annonc.2024.08.562
49th AEEH Congress 2024. Hepatic steatosis in premenopausal women as a risk factor for CDK4/6 inhibitor-induced hepatotoxicity in MBC. Madrid, Spain. February 14–16, 2024.
ESMO Congress 2023. Predictive factors for Drug-Induced Liver Injury in patients with ER-positive HER2-negative metastatic Breast Cancer treated with first-line CDK4/6 inhibitors. Madrid, Spain. October 20–24, 2023.
XVII Vall d’Hebron Scientific Research Day 2023. Predictive factors for DILI in patients with ER-positive HER2-negative metastatic Breast Cancer treated with first-line CDK4/6 inhibitors. Barcelona, Spain. November 24, 2023.
SEOM 2023. Características clinicopatológicas y moleculares de dos tumores poco frecuentes: carcinoma de apéndice cecal y adenocarcinoma de intestino delgado. Barcelona, Spain. September 19–22, 2023.
World Congress on Gastrointestinal Cancer (ESMO WGI) 2023. Comparison of clinicopathological and molecular features of two rare entities: appendiceal carcinoma and small bowel adenocarcinoma. Barcelona, Spain. June 28 – July 1, 2023.
ESMO Breast Cancer 2023. Liver toxicity in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line CDK4/6 inhibitors. Berlin, Germany. May 11–13, 2023.
SEOM 2021. HOSPITAL SCORE as a prognostic factor for readmission and Overall Survival (OS) in cancer patients admitted to a tertiary center. Barcelona, Spain. October 18–22, 2021.